On 8 July, Rubicon Research announced the acquisition of Cipla’s Meditab Specialties plant in Satara in Maharashtra. It is expected that the closing of the deal will be completed in two months. The Cipla’s Meditab plant currently manufactures oral liquid dosage and nasal inhalers. The acquisition is for an undisclosed sum. Meditab Specialities is a wholly owned subsidiary of Cipla.
A specialty pharma company, Rubicon Research operates out of four locations across India, the US and Canada. Rubicon is part of global equity investment company General Atlantic with US$ 53 billion in assets under management. “The acquisition of an oral liquid and nasal inhalers manufacturing facility advances our plan to offer a wider portfolio to our customers,” said Parag Sancheti, CEO of Rubicon Research.
The acquisition includes about 80 employees at Meditab’s Satara plant which Good Manufacturing Practices compliant and has been inspected by the UK regulatory authority for pharmaceuticals. It is apparently capable of manufacturing various oral liquid formulations. Rubicon will apply for additional regulatory approvals for the Satara plant from the US FDA, and other agencies.
